JP2005525356A - 抗癌剤としてのファルネシルタンパク質トランスフェラーゼ阻害剤 - Google Patents

抗癌剤としてのファルネシルタンパク質トランスフェラーゼ阻害剤 Download PDF

Info

Publication number
JP2005525356A
JP2005525356A JP2003571255A JP2003571255A JP2005525356A JP 2005525356 A JP2005525356 A JP 2005525356A JP 2003571255 A JP2003571255 A JP 2003571255A JP 2003571255 A JP2003571255 A JP 2003571255A JP 2005525356 A JP2005525356 A JP 2005525356A
Authority
JP
Japan
Prior art keywords
group
substituted
alkyl
compound
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003571255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525356A5 (OSRAM
Inventor
ヒュー ワイ． ジュ，
エフ． ジョージ ンジョロジ，
クーパー，　アラン　ビー．
ティモシー ジェイ． グジ，
ディナナス エフ． レーン，
マイナー，　キース　ピー．
ドール，　ロナルド　ジェイ．
ビオール モーピル ガールジャヴァラブハン，
サンサナム，　バマ
パトリック エー． ピント，
バンチャ ヴィバルブハン，
カーティック エム． カーティカー，
カルメン エス． アルヴァレズ，
バルドウィン，　ジョン　ジェイ．
リ，　ゲ
チャー−ユ ファン，
レイ エー． ジェームス，
ダブリュー． ロバート バイショップ，
ジェームス ジェイ−エス ワン，
ジャグディッシュ エー． デサイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005525356A publication Critical patent/JP2005525356A/ja
Publication of JP2005525356A5 publication Critical patent/JP2005525356A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003571255A 2002-02-27 2003-02-25 抗癌剤としてのファルネシルタンパク質トランスフェラーゼ阻害剤 Pending JP2005525356A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
PCT/US2003/005479 WO2003072549A1 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Publications (2)

Publication Number Publication Date
JP2005525356A true JP2005525356A (ja) 2005-08-25
JP2005525356A5 JP2005525356A5 (OSRAM) 2006-04-13

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003571255A Pending JP2005525356A (ja) 2002-02-27 2003-02-25 抗癌剤としてのファルネシルタンパク質トランスフェラーゼ阻害剤

Country Status (19)

Country Link
US (1) US7342016B2 (OSRAM)
EP (1) EP1492772A1 (OSRAM)
JP (1) JP2005525356A (OSRAM)
KR (1) KR20040098004A (OSRAM)
CN (1) CN100537542C (OSRAM)
AR (1) AR039557A1 (OSRAM)
AU (1) AU2003215389B2 (OSRAM)
BR (1) BR0308071A (OSRAM)
CA (1) CA2477328A1 (OSRAM)
CO (1) CO5611194A2 (OSRAM)
IL (1) IL163673A0 (OSRAM)
MX (1) MXPA04008303A (OSRAM)
NO (1) NO20044053L (OSRAM)
NZ (1) NZ534809A (OSRAM)
PE (1) PE20031038A1 (OSRAM)
PL (1) PL372335A1 (OSRAM)
RU (1) RU2004128465A (OSRAM)
TW (1) TW200303867A (OSRAM)
WO (1) WO2003072549A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
ATE417041T1 (de) * 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel
CA2568524A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2008501758A (ja) 2004-06-09 2008-01-24 グラクソ　グループ　リミテッド ピロロピリジン誘導体
EP1833481A1 (en) 2004-12-14 2007-09-19 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
AU2005319182A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
MY183404A (en) * 2006-12-19 2021-02-18 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
WO2023071601A1 (zh) * 2021-10-28 2023-05-04 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504724A (ja) * 1989-05-01 1992-08-20 シェリング・コーポレーション 置換ベンゾ〔５，６〕シクロヘプタピリジンの複素環式ｎ―オキシド誘導体、組成物およびその使用法
JPH08510760A (ja) * 1993-10-15 1996-11-12 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式アミドおよび三環式尿素化合物
JPH10505105A (ja) * 1995-03-24 1998-05-19 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の処置に有用な三環式アミドおよび三環式尿素化合物
JPH11501671A (ja) * 1995-12-22 1999-02-09 シェーリング コーポレイション Ｇ―タンパク質機能の阻害および増殖性疾患の処置に有用な三環式アミド
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
JP2001500505A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション Ｆｐｔインヒビターとして有用な三環式化合物
JP2004513885A (ja) * 2000-08-30 2004-05-13 シェーリング　コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターである三環式抗腫瘍化合物
JP2005515201A (ja) * 2001-12-03 2005-05-26 シェーリング　コーポレイション 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
AU8854091A (en) 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0929544B1 (en) 1996-09-13 2004-11-10 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU8253598A (en) 1997-06-17 1999-01-04 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
EP1156046A1 (en) 1997-06-17 2001-11-21 Schering Corporation Benzo(5,6)cyclohepta(1,2-B)pyridine derivatives for the inhibition of farnesyl protein transferase
KR100640672B1 (ko) 1997-06-17 2006-11-02 파마코페이아 드럭 디스커버리, 인크. 파르네실 단백질 트랜스퍼라제의 억제에 유용한 벤즈피리도 사이클로헵탄 화합물 및 이를 포함하는 약제학적 조성물
IL133393A0 (en) 1997-06-17 2001-04-30 Schering Corp Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
US5925648A (en) 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.
ATE293622T1 (de) 1998-12-18 2005-05-15 Schering Corp Farnesyl protein transferase inhibitoren
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
SI1255537T1 (sl) 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
ATE417041T1 (de) * 2003-08-07 2008-12-15 Schering Corp Neue farnesylproteintransferaseinhibitoren als antitumormittel

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504724A (ja) * 1989-05-01 1992-08-20 シェリング・コーポレーション 置換ベンゾ〔５，６〕シクロヘプタピリジンの複素環式ｎ―オキシド誘導体、組成物およびその使用法
JPH08510760A (ja) * 1993-10-15 1996-11-12 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式アミドおよび三環式尿素化合物
JPH10505105A (ja) * 1995-03-24 1998-05-19 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の処置に有用な三環式アミドおよび三環式尿素化合物
JPH11501671A (ja) * 1995-12-22 1999-02-09 シェーリング コーポレイション Ｇ―タンパク質機能の阻害および増殖性疾患の処置に有用な三環式アミド
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
JP2001500505A (ja) * 1996-09-13 2001-01-16 シェーリング コーポレイション Ｆｐｔインヒビターとして有用な三環式化合物
JP2004513885A (ja) * 2000-08-30 2004-05-13 シェーリング　コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターである三環式抗腫瘍化合物
JP2005515201A (ja) * 2001-12-03 2005-05-26 シェーリング　コーポレイション 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JPN6009043036, ＳＥＢＴＩ， Ｓ．Ｍ．， ｅｔ ａｌ．, Ｏｎｃｏｇｅｎｅ, １９, ｐｐ．６５８４−６５９３ （２０００） *
JPN6009043037, ＣＯＸ， Ａ．Ｄ．, Ｄｒｕｇｓ, ６１（６）, ｐｐ．７２３−７３２ （２００１） *
JPN6009043038, 福島 雅典（総編集）, メルクマニュアル（日本語版）, 第１６版第３刷, ｐｐ．１２１９−１２４７ （１９９５）, （有）メディカルブックサービス *
JPN6009043039, 吉田 清一ら, 癌と化学療法, ８（４）, ｐｐ．５４２−５５６ （１９８１） *
JPN6009043040, 星野 章ら, 臨床医, ９（１０）, ｐｐ．１５６０−１５６３ （１９８３） *
JPN6009043041, 横井 香平ら, 医学のあゆみ, １２９（１２）, ｐｐ．８１２−８１８ （１９８４） *
JPN6009043042, 吉田 清一ら, 現代医療, １６（１）, ｐｐ．２５２−２６３ （１９８４） *
JPN6009043043, 小川 一誠, 日本医事新報, （３２８３）, ｐｐ．３−１０ （１９８７） *
JPN6009043044, 栗原 稔, 日本医事新報, （３９０６）, ｐｐ．１−９ （１９９９） *
JPN6009043045, ＳＡＴＯ， Ｙ．, Ｊ． Ｋｙｏｔｏ Ｐｒｅｆ． Ｕｎｉｖ． Ｍｅｄ．, ９７（８）, ｐｐ．９９７−１０１４ （１９８８） *
JPN6009043046, ＳＵＮ， Ｊ．， ｅｔ ａｌ．, Ｃａｎｃｅｒ Ｒｅｓ．, ５９, ｐｐ．４９１９−４９２６ （１９９９） *
JPN6009043047, ＪＵＤＳＯＮ， Ｉ．， ｅｔ ａｌ．, Ｄｒｕｇｓ, ５９（Ｓｕｐｐｌ．４）, ｐｐ．２９−３６ （２０００） *

Also Published As

Publication number Publication date
CN100537542C (zh) 2009-09-09
PL372335A1 (en) 2005-07-11
RU2004128465A (ru) 2005-09-27
NZ534809A (en) 2007-12-21
CO5611194A2 (es) 2006-02-28
AU2003215389A1 (en) 2003-09-09
BR0308071A (pt) 2004-12-21
AR039557A1 (es) 2005-02-23
PE20031038A1 (es) 2004-01-10
NO20044053L (no) 2004-11-26
US20040122018A1 (en) 2004-06-24
CN1630641A (zh) 2005-06-22
TW200303867A (en) 2003-09-16
WO2003072549A1 (en) 2003-09-04
EP1492772A1 (en) 2005-01-05
IL163673A0 (en) 2005-12-18
CA2477328A1 (en) 2003-09-04
US7342016B2 (en) 2008-03-11
MXPA04008303A (es) 2005-11-23
KR20040098004A (ko) 2004-11-18
AU2003215389B2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
JP2005525356A5 (OSRAM)
AU2009215534A1 (en) Compounds that are ERK inhibitors
US20030229099A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
US7342016B2 (en) Farnesyl protein transferase inhibitors as antitumor agents
JP2005515201A (ja) 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用
AU2001288451C1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
US7557107B2 (en) Farnesyl protein transferase inhibitors as antitumor agents
AU2001288451A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
CN101400656A (zh) 作为法呢基蛋白转移酶抑制剂的哌嗪衍生物
US20060205755A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
HK1087122B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2007202115A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060126

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20100604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110302